Navigation Links
Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate

The improvements made in diagnoses and treatment of the fatal childhood cancer acute lymphoblastic leukemia (ALL) will result in a cure rate of 90%, according to researchers belonging to the St. Jude Children's Research Hospital.//

The progressive improvement in the cure rate since 1962, when only 4% of children with ALL survived, reflects in large part the more effective use of existing drugs and the incorporation of sophisticated genetic technologies to personalize treatments. Research findings at St. Jude have enabled clinicians to identify patients for whom standard treatment is most likely to fail, and who should therefore be treated more aggressively. These findings have also allowed clinicians to choose the optimal drugs and drug dosages for individual patients.

The improvements in ALL treatment are also helping to reduce the long-term toxic side effects of the therapy by enabling clinicians to reduce or avoid the use of certain drugs or radiation that can damage major organs or cause secondary cancers.

A 90% cure rate for ALL is quite possible in the near future if we continue to incorporate the breakthroughs of past decades and successfully overcome the remaining challenges. This reflects the ability of St. Jude to provide free treatment to all children regardless of their ethnic or racial backgrounds or their ability to pay, and to tailor the treatment according to their specific needs.

That success is based to a large extent on the work done at St. Jude and elsewhere in identifying specific mutations in leukemic cells that strongly suggest the likelihood that treatment will fail the child, the authors reported. Adding to the complexity of the patient's response to treatment are differences in how quickly the body activates, breaks down or eliminates specific cancer drugs.

Pharmacogenomics is the study of the effects of different genes on the response to drugs. Such studies often include the analysis of the roles of hundreds or even thousands of genes.

Another significant contribution made by St. Jude researchers is the measurement of minimal residual disease (MRD), that is the small populations of leukemic cells that survive initial treatment (induction therapy). These cells can replenish the population of leukemic cells and cause the patient to relapse.

Edited (ANI)

Related medicine news :

1. Acute Measles Supresses HIV Replication
2. Severe Acute respiratory Syndrome (SARS)
3. WHO Travel Advice to prevent spread of "Severe Acute Respiratory Syndrome (SARS)
4. Acute Pancreatitis On The Rise Due To Alcohol Consumption
5. Promised Drug Doesnt Help Acute Heart Failure
6. Gene Fusion Test to screen children’s with Acute Lymphoblastic Leukemi
7. Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia
8. Acute Gastroenteritis Responds To Treatment With Either Gatorade Or Pedialyte
9. Acute Shortage Of Neurosurgeons In India: One Surgeon For Every 1 Million!
10. Acute Shortage Of Dentists in UK: Oral Care for Elders To Suffer A Setback
11. Women Health : Acute Stress, A Shot in The Arm For Flu?
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
Breaking Medicine Technology: